Seeing is Believing – Detection Made Easy Part 5: Fluorescence Detectors

News from LabRulezLCMS Library - Week 37, 2026

ISC 2026 officially opened in Prague on Sunday, September 6, bringing the international separation science community together at the Prague Congress Centre. The first day began with six Short Courses covering topics from analytical procedure lifecycle and mass spectral interpretation to HILIC, oligonucleotides, LC/MS data analysis, and supercritical fluids. In the afternoon, conference chairs Michal Holčapek and Lucie Nováková welcomed participants during the Opening Ceremony, followed by the J.F.K. Huber Medal Award Ceremony. The scientific program then moved into its first plenary session, spanning spintronics, single-cell proteomics and robust LC-MS, and rapid evaporative ionisation mass spectrometry. The opening day concluded with the Welcome Reception, giving participants their first opportunity to meet colleagues from around the world and begin a week of scientific exchange, new ideas, and chromatography in the heart of Prague.<h4>Sunday, September 6th</h4><h5>8:30–15:45 Short Courses 3 - 8</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Short_Courses_Koen_Sandra_176f1c6d52.jpg" alt="ISC: ISC 2026 - Day 1: Short Course SC 6 Oligonucleotides and Other Biopharmaceuticals (Koen Sandra)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Short_Courses_Koen_Sandra_176f1c6d52.jpg 235w," sizes="100vw" width="1600" height="1067"><h5>16:00–16:30 Opening Ceremony</h5><ul><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/articles?search=hol%C4%8Dapek">Michal Holčapek</a>, Czech Republic</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/articles?search=Lucie+Nov%C3%A1kov%C3%A1">Lucie Nováková</a>, Czech Republic</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Opening_Novakova_and_Holcapek_bbf9dd44e3.jpg" alt="ISC: ISC 2026 - Day 1: Michal Holčapek and Lucie Nováková opened ISC 2026" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Opening_Novakova_and_Holcapek_bbf9dd44e3.jpg 235w," sizes="100vw" width="1600" height="1067"><h5>16:30–17:00 Award Ceremony</h5><ul><li>J.F.K. Huber Medal (awarded by the Austrian Society for Analytical Chemistry)</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_JFK_Huber_Award_winner_Dave_846f6a5dff.jpg" alt="ISC: ISC 2026 - Day 1: Davy Guillarme as a 2026 recipient of the J.F.K. Lecture Award of the Austrian Society of Analytical Chemistry" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_JFK_Huber_Award_winner_Dave_846f6a5dff.jpg 235w," sizes="100vw" width="1600" height="1066"><h4>Plenary lectures</h4><h5>17:00 - 17:30 Spintronics: A new paradigm in digital bits</h5><ul><li>Tomáš Jungwirth, Czech Republic&nbsp;&nbsp;&nbsp;&nbsp;</li></ul>Besides the rapid developments in the big world of cloud data centers and AI, a remarkable paradigm shift is occurring on the level of the smallest “elementary particle” of information technologies – the single physical bit. For the first time in the history of microprocessor chips, semiconductor bits are being replaced by a fundamentally distinct technology. The technology is based on magnets and is called spintronics. All major developers and manufacturers of the advanced chip technologies are now implementing these new spintronic bits. Not across the entire microprocessor chip, but in some of its vital memory parts. The transition to the spintronic bits is happening because further miniaturization of semiconductor bits has become prohibitively expensive or even reached fundamental physical limits. In the talk we will introduce the distinct physical principle behind the spintronic bits, and highlight some of the recent adbances in spintronics research and development.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Tomas_Jungwirth_dd6eeca2b5.jpg" alt="ISC: ISC 2026 - Day 1: Spintronics: A new paradigm in digital bits (Tomáš Jungwirth, Czech Republic)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Tomas_Jungwirth_dd6eeca2b5.jpg 245w," sizes="100vw" width="1595" height="1008"><h5>17:30 - 18:00 Single cell proteomics requires robust LC-MS: Unexpected findings bring new biological understanding</h5><ul><li>Jennifer Van Eyk, USA&nbsp;&nbsp;&nbsp;&nbsp;</li></ul>Underlying precision medicine is the concept that an individual’s Omic signature (including the proteome) will provide a physician with clinically actionable diagnosis and a subsequent mechanistic therapeutic route that is appropriate for a particular person. This concept is based on the idea of pathological heterogeneity and recognizes the impact of differences in the heath state of individuals. The deployment of single cell technologies has demonstrated heterogeneity within a single cell type which impacts the degree of cellular heterogeneity within an organ. Unlike bulk proteomic approaches, which average signals across heterogeneous populations, single-cell proteomics captures the molecular diversity of cell. Today single-cell proteomics can provide high-resolution characterization of protein quantities and variability within the structural composition and signaling dynamics within individual cells which requires robust, precise and sensitive liquid chromatography and mass spectrometry (LC-MS) workflows with sufficient throughput to quantitatively analyze 1000s of single cells.We have developed stable and precise single cell LC-MS workflow based on high-flow, dual trap with a single analytical column system that can achieve 96 samples per day. Furthermore, we have coupled this with a novel parallel sample preparation method on demand within the autosampler reducing sample lose and matching throughput with the LC-MS. Here, we have investigated the proteomic heterogeneity of cardiac muscle cells, cardiomyocytes, the specialized cells that contain the contractile proteins and which are responsible for the heart contraction and relaxation. By applying single-cell proteomics to cardiomyocytes isolated from human and mouse hearts, as well as human iPSC-derived cardiomyocytes, we uncovered previously unrecognized cellular subpopulations distinguished by differences in contractile and metabolic protein expression. As well unexpectedly, we unambiguously identified proteins traditionally considered absent in adult cardiomyocyte, such as slow skeletal troponin T, previously thought to be restricted to fetal or skeletal muscle or those proposed to be limited to non-cardiac cell types (e.g., neuronal proteins) or species (e.g., myosin heavy chain 7b). This suggests an unexpected fluidity in cardiac protein expression. Furthermore, single cell proteomics has provided critical insight into protein-level remodeling in heart failure, where the same single amino acid mutation in a contractile protein can give rise to diverse clinical phenotypes. At the single cell level, the mutant protein dosage in each cell drives a continuum of subproteomic pathological alterations. Only with precise protein quantification at the single cell level, is this understanding possible – all of which hinges on the LC-MS performance.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Jennifer_Van_Eyk_f8641196ff.jpg" alt="ISC: ISC 2026 - Day 1: Single cell proteomics requires robust LC-MS: Unexpected findings bring new biological understanding (Jennifer Van Eyk, USA)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Jennifer_Van_Eyk_f8641196ff.jpg 235w," sizes="100vw" width="1600" height="1066"><h5>18:00 - 18:30 Rapid evaporative ionisation mass spectrometry: From MSI to LC-MS</h5><ul><li>Zoltan Takats, United Kingdom&nbsp;&nbsp;&nbsp;&nbsp;</li></ul>Rapid Evaporative Ionisation Mass Spectrometry (REIMS) was originally developed for mass spectrometry-guided surgery applications, enabling the direct, real-time analysis of surgical aerosols for in-situ histological identification of tissues in cancer surgery. Coupling the technique with various surgical and non-surgical lasers led to the recognition, that the technique has comparable sensitivity to other, widely used desorption ionisation methods including DESI and MALDI. Laser Ablation REIMS using 3 μm wavelength picosecond lasers was demonstrated to provide sub-cellular resolution metabolic and lipidomic images at 2-5 μm spatial resolution, with clear visualisation of cellular nuclei. The method was subsequently used for regenerative neuroscience and cancer biology applications. The unexpectedly high sensitivity of the method (fg amounts of lipids and metabolites / pixel) encouraged us to attempt using REIMS as an LC-MS ion source. The current commercially available REIMS instrumentation utilises the so-called matrix-assited REIMS technology, involving the co-introduction of a polar solvent (water, acetonitrile or aliphatic alcohols) together with the sample aerosol. The fused droplets containing solvent and soluble components of the aerosol are introduced into the vacuum where they impact a heated (≈900 ºC) surface resulting in their 'rapid evaporation' yielding the detected ion population. In this context, the ionisation matrix was replaced by LC effluent, leading to a fundamentally new way of ionisation. The new technique termed LC-REIMS was characterised using reversed phase LC applications including lipid and metabolite profiling. The new ionisation method was found to exhibit high similarity to sonic spray and related techniques, in spite of the high temperature involved. Analytical sensitivity for complex lipids and amino acids were found to be comparable to those in ESI or APCI, albeit the relative response factors followed markedly different trends. As the technology represents an LC-MS coupling without any requirement for pressurised gas or high voltage, it has significant application potential for field instrumentation including industrial process control or security screening.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Zoltan_Takats_3e0c11a22e.jpg" alt="ISC: ISC 2026 - Day 1: Rapid evaporative ionisation mass spectrometry: From MSI to LC-MS (Zoltan Takats, United Kingdom)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Zoltan_Takats_3e0c11a22e.jpg 129w," sizes="100vw" width="1600" height="1933"><h5>18:30–19:30 Welcome Reception</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Welcome_reception_36bfcb7276.jpg" alt="ISC: ISC 2026 - Day 1: Welcome reception" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Welcome_reception_36bfcb7276.jpg 235w," sizes="100vw" width="1600" height="1067"><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Welcome_reception_2_4ae69091a6.jpg" alt="ISC: ISC 2026 - Day 1: Welcome reception" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Welcome_reception_2_4ae69091a6.jpg 235w," sizes="100vw" width="1600" height="1067">

ISC 2026 - Day 1

Article

Product

Events

Application

Academy

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

GHK (or GHK-Cu) analysis

Targeted HPLC analysis of GHK or GHK-Cu in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The GHK (or GHK-Cu) Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of GHK or GHK-Cu in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About GHK and GHK-Cu</h4>GHK (Gly-His-Lys) is a naturally occurring tripeptide with a high affinity for copper. When it binds copper(II), it forms the GHK-Cu complex, also known as Copper Tripeptide-1 or Copper Peptide.GHK and particularly its copper complex GHK-Cu have been studied in connection with tissue remodeling, wound healing, and skin regeneration.<h4>Key Features</h4><ul><li>Targeted identification and quantification of GHK or GHK-Cu</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: GHK, GHK-Cu</li><li>Other names (GHK-Cu): Copper Tripeptide-1, Copper Peptide</li><li>CAS number – GHK: 49557-75-7</li><li>Molecular weight – GHK: 340 Da</li><li>Sequence – GHK: Gly-His-Lys</li><li>CAS number – GHK-Cu: 89030-95-5</li><li>Molecular weight – GHK-Cu: 403.5 Da</li><li>Sequence – GHK-Cu: Gly-His-Lys-Cu</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for GHK and GHK-Cu. It does not automatically screen the sample for other peptides, copper complexes, related compounds, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Kisspeptin Analysis

Targeted HPLC analysis of kisspeptin-10 in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Kisspeptin Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of kisspeptin in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Kisspeptin</h4>Kisspeptins are naturally occurring neuropeptides derived from the KISS1 gene. The form covered by the supplied analysis parameters corresponds to kisspeptin-10 (KP-10), a 10-amino-acid peptide with the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2.Kisspeptin-10 activates the kisspeptin receptor KISS1R, also known as GPR54, and plays an important role in the neuroendocrine regulation of reproduction by stimulating gonadotropin-releasing hormone (GnRH) signalling.<h4>Key Features</h4><ul><li>Targeted identification and quantification of kisspeptin</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Kisspeptin</li><li>CAS number: 374675-21-5</li><li>Molecular weight: 1302 Da</li><li>Sequence: H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for kisspeptin. It does not automatically screen the sample for other kisspeptin forms, related peptides, degradation products, contaminants, or undeclared substances.</li><li>The CAS number and sequence specified for this analysis correspond to kisspeptin-10 (KP-10).</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

KLOW (GHK or GHK-Cu / TB-500 / BPC-157 / KPV) Analysis

Targeted HPLC analysis of KLOW blends containing GHK or GHK-Cu, TB-500, BPC-157, and KPV for identification and amount determination.

The KLOW Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of GHK or GHK-Cu, TB-500, BPC-157, and KPV in a peptide blend.The analysis is intended for lyophilised KLOW samples and is performed by HPLC, with results reported in milligrams per vial. Peptide purity cannot be determined in peptide blends because impurities from the individual components may overlap during analysis.<h4>About the Analyzed Peptides</h4>GHK is the tripeptide Gly-His-Lys, while GHK-Cu is its copper complex. Both forms have been investigated in connection with tissue remodeling and wound-healing processes.TB-500 is associated with an N-terminal acetylated fragment of thymosin β4, while BPC-157 is a synthetic pentadecapeptide investigated primarily in preclinical models of tissue repair. KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH) and has been studied for its anti-inflammatory properties.<h4>Key Features</h4><ul><li>Targeted identification and quantification of GHK or GHK-Cu, TB-500, BPC-157, and KPV</li><li>Designed for KLOW peptide blends</li><li>Suitable for lyophilised vials</li><li>Analysis by HPLC</li><li>Results reported in mg per vial</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Average turnaround time of 7 business days</li><li>Peptide purity is not determined for blends</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: GHK or GHK-Cu, TB-500, BPC-157, KPV</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format: mg per vial</li><li>Minimum sample amount: One whole unopened vial with lyophilisate</li><li>Average turnaround time: 7 business days</li><li>Important note: Peptide purity is not measured</li></ul><blockquote>Important Notice<ul><li>Peptide purity cannot be determined in this blend because impurities from the individual peptides may overlap and cannot be reliably distinguished from one another.</li><li>This analysis is specifically intended for KLOW blends containing GHK or GHK-Cu, TB-500, BPC-157, and KPV. It does not automatically screen the sample for other peptides, related compounds, contaminants, or undeclared substances.</li><li>For analysis, one whole unopened vial containing lyophilisate is required.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

KPV analysis

Targeted HPLC analysis of KPV (2-oxo-5-phenylpentanoic acid) in lyophilised vials and raw API powders for identity and amount determination.

The KPV Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the purity of KPV in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with purity. Raw API powders can be evaluated using purity in % (m/m).<h4>About KPV</h4>In this analysis, KPV refers to 2-oxo-5-phenylpentanoic acid, also known as 5-phenyl-2-keto-valeric acid. It is a small organic α-keto acid with the molecular formula C11H12O3.2-Oxo-5-phenylpentanoic acid has been used as a research compound in biochemical and medicinal chemistry studies, including investigations involving enzyme–substrate interactions and α-keto acid derivatives.<h4>Key Features</h4><ul><li>Targeted identification and quantification of KPV</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: KPV</li><li>Other name: 2-oxo-5-phenylpentanoic acid</li><li>CAS number: 88768-11-0</li><li>Molecular weight: 192&nbsp;</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>In this analysis, KPV refers specifically to 2-oxo-5-phenylpentanoic acid (CAS 88768-11-0).</li><li>This analysis is specifically intended for KPV. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Livagen analysis

Targeted HPLC analysis of Livagen in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Livagen Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Livagen in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Livagen</h4>Livagen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Ala (KEDA). It has been investigated as a short peptide bioregulator, particularly in experimental research related to liver cells and hepatic function.Experimental studies have examined the effects of Livagen on protein synthesis in hepatocytes, liver tissue models, and selected physiological processes. The available evidence is primarily based on preclinical and laboratory research.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Livagen</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Livagen</li><li>Molecular weight: 461</li><li>Sequence: Lys-Glu-Asp-Ala</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Livagen. It does not automatically screen the sample for other peptides, related compounds, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

LL-37 analysis

Targeted HPLC analysis of LL-37 in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The LL-37 Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of LL-37 in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About LL-37</h4>LL-37 is a naturally occurring 37-amino-acid human cathelicidin-derived peptide involved in innate host defense. It is generated from the precursor protein hCAP18 and exhibits antimicrobial activity against a broad range of microorganisms.In addition to its antimicrobial properties, LL-37 has been investigated for immunomodulatory activity and its involvement in processes such as inflammation, angiogenesis, and wound healing.<h4>Key Features</h4><ul><li>Targeted identification and quantification of LL-37</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: LL-37</li><li>CAS number: 597562-32-8</li><li>Molecular weight: 4493</li><li>Sequence: H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for LL-37. It does not automatically screen the sample for other cathelicidin-derived peptides, related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Mazdutide analysis

Targeted HPLC analysis of mazdutide in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Mazdutide Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of mazdutide in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Mazdutide</h4>Mazdutide is a peptide-based dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Activation of these two receptors influences glucose metabolism, appetite regulation, and energy balance.Mazdutide has been studied in clinical trials primarily in connection with body-weight management and glycemic control.<h4>Key Features</h4><ul><li>Targeted identification and quantification of mazdutide</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Mazdutide</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for mazdutide. It does not automatically screen the sample for other GLP-1 or glucagon receptor agonists, related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Melanotan 1 analysis

Targeted HPLC analysis of Melanotan 1 in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Melanotan 1 Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Melanotan 1 in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Melanotan 1</h4>Melanotan 1 (MT-1), also known as afamelanotide, is a synthetic 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (α-MSH). It acts as an agonist of the melanocortin-1 receptor (MC1R) and stimulates the production of eumelanin, the brown-black pigment involved in skin pigmentation and photoprotection.Melanotan 1 has been investigated extensively in studies of melanocortin signalling and pigmentation. Afamelanotide is also the active substance in the medicinal product Scenesse, authorised in the European Union for the prevention of phototoxicity in adults with erythropoietic protoporphyria.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Melanotan 1</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Melanotan 1</li><li>Other name: MT-1</li><li>CAS number: 75921-69-6</li><li>Molecular weight: 1647 Da</li><li>Sequence: Ac-DL-Ser-DL-Tyr-DL-Ser-DL-Nle-DL-Glu-DL-His-DL-Phe-DL-Arg-DL-Trp-Gly-DL-Lys-DL-Pro-DL-Val-NH2</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Melanotan 1. It does not automatically screen the sample for <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2573">Melanotan 2</a>, other melanocortin-related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Melanotan 2 analysis

Targeted HPLC analysis of Melanotan 2 in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Melanotan 2 Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Melanotan 2 (MT-2) in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Melanotan 2</h4>Melanotan 2 (MT-2) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It acts as an agonist of melanocortin receptors and has been investigated primarily for its effects on melanin production, pigmentation, and other melanocortin-mediated processes.Unlike<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2572"> Melanotan 1</a>, Melanotan 2 interacts with several melanocortin receptor subtypes rather than acting predominantly through MC1R. It remains primarily a research compound.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Melanotan 2</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Melanotan 2</li><li>CAS number: 121062-08-6</li><li>Molecular weight: 1024</li><li>Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-NH2</li><li>Testing method: HPLC</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Melanotan 2. It does not automatically screen the sample for <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2572">Melanotan 1</a>, other melanocortin-related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

MGF analysis

Targeted HPLC analysis of MGF in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The MGF Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of MGF in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About MGF</h4>MGF (Mechano Growth Factor) is a synthetic research peptide studied primarily in relation to the response of skeletal muscle to mechanical stress and injury.Experimental studies have examined its potential effects on muscle cell proliferation and migration, as well as processes associated with muscle tissue regeneration.<h4>Key Features</h4><ul><li>Targeted identification and quantification of MGF</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: MGF</li><li>Molecular weight: 2868 Da</li><li>Sequence: NH2-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-COOH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for MGF. It does not automatically screen the sample for IGF-1, other IGF-related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products focused on HPLC - page 4

Related content

ISC 2026 - Day 1

News from LabRulezLCMS Library - Week 37, 2026

Seeing is Believing – Detection Made Easy Part 5: Fluorescence Detectors